The pharmaceutical industry operates under an exceptionally high level of demand. A failure in manufacturing, storage, distribution, traceability or IT systems translates into financial losses, third-party claims, regulatory problems or business downtime. That is why talking about insurance for the pharmaceutical industry is not talking about a standard policy, but about a protection programme tailored to the type of company, the product and the point in the chain at which it operates.
In Spain, the sector’s activity is closely linked to the control of manufacturing, distribution and the legality of operators and suppliers. The AEMPS (Spanish Agency for Medicines and Medical Devices) requires verification of the legality of clients and suppliers within the pharmaceutical chain. Furthermore, the regulatory framework for distribution emphasises that chain control is essential to guarantee adequate quality, storage and supply.
Without further ado, let us look at all the key aspects of insurance for the pharmaceutical industry.
What is insurance for the pharmaceutical industry
Insurance for the pharmaceutical industry consists of insurance solutions designed to cover the risks specific to laboratories, manufacturers, importers, warehousers, distributors and other companies linked to the pharma sector. Their function is to protect both the company’s assets and its profit and loss account, its operational continuity and its position in the face of claims.
Not all companies in the sector require the same coverage. A pharmaceutical laboratory that manufactures or packages medicines does not face exactly the same risks as a pharmaceutical distributor or a company providing auxiliary services to the supply chain. This is why it is advisable to work with a broker that analyses activity, processes, turnover, markets, technological dependency and regulatory exposure.
In the business environment, at Ambler we frame our proposition precisely from risk management for companies, with specific solutions for civil liability, cybersecurity, material damage, goods in transit and D&O.
Why the pharmaceutical industry needs specific policies
The pharmaceutical industry works with products subject to health controls, quality obligations, storage requirements, documentary traceability, process validation and, in many cases, a strong dependency on suppliers and digital systems.
The Ministry of Health itself positions the pharmaceutical industry as a strategic sector for access to medicines, system sustainability and competitiveness. According to Farmaindustria, the sector’s relevance is key: more than 27.2 billion euros in added value in 2023, equivalent to 1.9% of GDP, 56,325 direct jobs and more than 270,000 total jobs, as well as 21.9 billion euros in pharmaceutical exports recorded that year.
An insurance programme for pharmaceutical companies tends to be more comprehensive because it must respond, among other things, to:
- Third-party damage caused by products or activity.
- Incidents in manufacturing or storage.
- Problems during goods in transit.
- Supplier failures or supply chain disruptions.
- Data breaches or cyber risk attacks.
- Claims against directors and executives.
- Loss of profit due to business interruption.
Most common risks in laboratories, manufacturers and distributors
1. Third-party damage claims
One of the clearest exposures is civil liability. It can arise from operational errors, damage caused at third-party premises, product defects or losses linked to the insured activity. In companies with sensitive products, this area must be reviewed in great detail.
2. Damage to premises, machinery or stock
Material damage can affect warehouses, laboratories, equipment, cold rooms, climate control systems, technical furniture or stored goods. In the pharma sector, moreover, it is not enough to assess the building or its contents: storage conditions, replacement, obsolescence and recovery time must all be analysed.
3. Distribution and logistics incidents
Spanish pharmaceutical distribution regulations emphasise the control of the chain, conservation and adequate supply. When a product is in transit, exposure to loss, theft, physical damage, logistical errors or in-transit incidents increases.
4. Digital risk
Many companies in the sector handle sensitive data, critical systems, traceability, ERP, supplier communications and quality documentation. INCIBE highlights the importance of cybersecurity crisis management in companies and offers specific guides to strengthen operational stability in the face of incidents.
5. Operational downtime
A fire, a breakdown, a contamination incident, a cyberattack or a logistical problem can cause business interruption. In an environment of tight margins and supply commitments, this item can be more serious than the initial damage.
Recommended coverage in pharmaceutical industry insurance
When designing an insurance programme for the pharmaceutical industry, at Ambler we recommend considering these options:
Pharmaceutical civil liability insurance
It must examine the company’s specific activity and its possible exposure to third parties. Our civil liability insurance for companies includes protection against claims and legal defence. In pharma, this policy must analyse limits, exclusions, territorial scope and possible extensions.
Material damage insurance
Very useful for protecting physical assets and the financial impact resulting from damage. It seeks to protect premises, properties and the profit and loss account when activity is halted due to damage suffered.
Goods in transit insurance
Highly relevant when there are domestic or international shipments, logistics intermediaries, temperature-controlled goods or high-value merchandise.
Cyber insurance
To protect information, systems, continuity and costs arising from digital incidents. INCIBE stresses the need to prepare for crisis management and the impact of incidents on suppliers and the supply chain.
D&O for directors and executives
In organisations with sensitive regulatory, contractual, financial or employment decisions, D&O insurance is decisive. The coverage is designed so that directors and executives can face claims from shareholders, employees, regulators or other interested parties.
Complementary coverage to consider
Depending on activity and size, it may also be worth reviewing:
- product recall
- group accident insurance
- machinery breakdown
- loss of profit
- environmental coverage
- extended legal defence
- extensions for critical suppliers or external warehouses
Summary table of insurance for the pharmaceutical industry
| Policy | What it covers | When it is advisable |
| Pharmaceutical civil liability | Third-party claims and legal defence | If the company manufactures, distributes or markets products |
| Material damage | Premises, equipment, stock and losses from damage | If the activity depends on physical assets |
| Goods in transit | Goods in transit | If there are domestic, international or temperature-controlled shipments |
| Cyber insurance | Data, systems and operational continuity | If the company depends on digital environments |
| D&O | Liability of directors and executives | If there are sensitive regulatory, financial or employment decisions |
| Complementary coverage | Product recall, breakdown, loss of profit and other extensions | If the activity requires broader protection |
What influences the price of insurance for pharmaceutical companies
The cost of pharmaceutical industry insurance does not depend solely on turnover. Insurers typically assess:
- actual type of activity
- whether the company manufactures, stores, distributes or provides services
- type of medicine or medical device
- volume and value of stock
- dependency on refrigeration or special storage conditions
- claims history
- export activity or international presence
- level of physical and digital security
- requested limits and indemnities
- network of suppliers and logistics operators
That is why comparing on price alone is usually a mistake. In this sector, the quality of coverage, sub-limits, deductibles and exclusions matter far more.
How to choose insurance for the pharmaceutical industry
If your company wants to get its pharmaceutical policy right, follow this order:
- Define the activity and processes precisely.
- Identify where your greatest risks lie: product, premises, data, logistics chain or management.
- Review contracts with clients, suppliers and operators.
- Check what coverage already exists and where there are gaps.
- Verify insured sums, exclusions and defence limits.
- Request a technical review with our experts.
A good decision does not mean taking out many policies, but taking out the right ones and coordinating them with each other.
9 signs that your current policy has fallen short
These signs usually indicate that it is worth reviewing the programme:
- The company has started exporting
- It has changed premises or expanded capacity
- It is working with new logistics operators
- It has incorporated more complex digital systems
- The value of its stock has increased
- It has entered new product lines
- It depends on a critical supplier
- The policy does not mention key business risks
- The last review was carried out years ago
How we can help you at Ambler
In companies of this type, our experts are responsible for translating real activity into a risk map and finding a coherent solution across civil liability, cyber risks, material damage, goods in transit and director protection.
We work in the business segment from a risk management perspective and offer, among others, business insurance, civil liability insurance, cybersecurity insurance, material damage insurance and D&O insurance.
Frequently asked questions about insurance for the pharmaceutical industry
What insurance does a pharmaceutical company need?
It depends on whether it manufactures, stores, distributes or provides services. Even so, it is usual to review civil liability, material damage, cybersecurity, goods in transit, D&O and loss of profit due to business interruption.
What does pharmaceutical civil liability insurance cover?
It usually covers third-party claims for damage caused during the insured activity, as well as legal defence. The exact scope varies depending on the policy, the activity and the agreed exclusions.
Is insurance compulsory in the pharmaceutical industry?
There is no single valid answer for every company in the sector. The specific need depends on the activity, the contractual framework and the type of risk assumed. The prudent approach is to review each case with specialist advice rather than relying on a general assumption.
How much does insurance for a pharmaceutical laboratory cost?
There is no standard rate. Factors include the activity, turnover, premises, stock value, claims history, export activity, contracted limits and regulatory exposure.
What happens if there is a product recall?
The impact can include direct costs, reputational harm, claims and logistical problems. Not all policies cover this scenario equally, so it is worth expressly checking whether a product recall guarantee exists and under what conditions.
How do you choose insurance for the pharmaceutical industry without overpaying?
The key is not to choose the lowest price, but the right coverage. First the real risk is analysed, and then policy quality, limits, deductibles and exclusions are compared.
Which pharmaceutical industry insurance policies are most important for a distributor?
For a pharmaceutical distributor, the priorities are usually civil liability, goods in transit insurance, material damage, business interruption protection and cyber insurance if it works with critical systems.
The security of being well advised
Pharmaceutical industry insurance must respond to a clear reality: the sector works with sensitive products, regulatory demands, critical logistics and strong reputational and financial exposure. That is why a pharma company should not limit itself to taking out a basic policy, but should coordinate a review of its civil liability, material damage, cyber risks, goods in transit and potential business interruption.
If your company wants to review its policies with technical criteria and a business-focused approach, a good option is to work with our team to study which coverage structure best fits your activity, your contracts and your actual level of exposure.
We have been helping more than 500 clients protect what matters most to them since 1991, with close, specialist and risk-tailored advice. Contact us today and get a bespoke proposal for your company.